About cxrx

Concordia International Corp (NASDAQ: CXRX)
Latest News

Shopping card with boxes labelled REITs, ETFs, Bonds, Stocks
Investing

No-Deal Brexit Will Have a Direct Impact on This Canadian Stock

Advanz Pharma Corp's (TSX:ADVZ) sales are heavily exposed to Britain's economy. A messy Brexit could have a direct impact, according…

Read more »

Investing

Legal Marijuana Could Be a Solution to the Opioid Epidemic! 1 Pharma Company That May Wish to Get Into the Weed Space

Here's a company that may make a splash in the cannabis-based pharmaceuticals space, and it's not a producer like Canopy…

Read more »

The Motley Fool
Investing

What Cannabis Stocks and Valeant Pharmaceuticals Intl Inc. (TSX:VRX) Have in Common

Here's what Canadian cannabis firms and Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) have in common. Hint: a lot.

Read more »

The Motley Fool
Investing

A Complete Disaster: Inside Concordia International Corp.’s Worst Quarter Yet

Here's a postmortem look at Concordia International Corp.'s (TSX:CXR)(NASDAQ:CXRX) brutal third-quarter earnings release.

Read more »

The Motley Fool
Investing

Concordia International Corp.: A Safe Buy?

Concordia International Corp. (TSX:CXR)(NASDAQ:CXRX) is a risky, debt-ridden company that could grow quite handsomely if a series of steps are…

Read more »

The Motley Fool
Dividend Stocks

How Will a Trump or Clinton Presidency Affect Your Portfolio?

Do you own Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) or TransCanada Corporation (TSX:TRP)(NYSE:TRP) shares? Then pay attention to this election cycle.

Read more »

The Motley Fool
Investing

Is Concordia International Corp. a Smart Buy at These Prices?

Because of too much debt and a reduction in revenue, Concordia International Corp. (TSX:CXR)(NASDAQ:CXRX) is a risky investment.

Read more »

The Motley Fool
Dividend Stocks

Concordia International Corp.’s Latest 50% Drop Is Attracting Some Institutional Investors

Concordia International Corp. (TSX:CXR)(NASDAQ:CXRX) is caught in the wake of dismal earnings reports, negative sentiment about the pharmaceutical industry’s pricing…

Read more »